文献速递免疫规划传染病防控与疫情报告

COVID-19疫苗在≥65岁成人中预防住院的效果—COVID-NET,13州,2021年2-4月

Effectiveness of COVID-19 Vaccines in Preventing Hospitalization Among Adults Aged ≥65 Years - COVID-NET, 13 States, February-April 2021.
PubMed 文献 · MMWR Morb Mortal Wkly Rep · 2021-08-13

该研究基于COVID-NET监测网络,分析2021年2月1日至4月30日期间7,280例≥65岁患者的data,评估三种紧急使用授权COVID-19疫苗预防住院的真实世界效果。结果显示,完整接种对65-74岁和≥75岁成人预防COVID-19相关住院均有高效力,支持提高该年龄组疫苗接种覆盖率。

要点

  • 65-74岁成人完整接种预防住院效力:Pfizer-BioNTech 96%,Moderna 96%,Janssen 84%。
  • ≥75岁成人完整接种预防住院效力:Pfizer-BioNTech 91%,Moderna 96%,Janssen 85%。
  • 三种疫苗对≥65岁成人预防COVID-19相关住院均高度有效,应努力提高接种覆盖率。

核心结论

  • 美国紧急使用授权的COVID-19疫苗在≥65岁成人中预防COVID-19相关住院高度有效。
  • 应努力提高该年龄组的疫苗接种覆盖率以降低住院风险。

主要发现

  • 65-74岁成人完整接种预防住院效力:Pfizer-BioNTech 96%(95%CI 94%-98%),Moderna 96%(95%CI 95%-98%),Janssen 84%(95%CI 64%-93%)。
  • ≥75岁成人完整接种预防住院效力:Pfizer-BioNTech 91%(95%CI 87%-94%),Moderna 96%(95%CI 93%-98%),Janssen 85%(95%CI 72%-92%)。

临床怎么用

  • 在≥65岁成人中推广COVID-19疫苗接种,以预防COVID-19相关住院。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Clinical trials of COVID-19 vaccines currently authorized for emergency use in the United States (Pfizer-BioNTech, Moderna, and Janssen [Johnson & Johnson]) indicate that these vaccines have high efficacy against symptomatic disease, including moderate to severe illness (1-3). In addition to clinical trials, real-world assessments of COVID-19 vaccine effectiveness are critical in guiding vaccine policy and building vaccine confidence, particularly among populations at higher risk for more severe illness from COVID-19, including older adults. To determine the real-world effectiveness of the three currently authorized COVID-19 vaccines among persons aged ≥65 years during February 1-April 30, 2021, data on 7,280 patients from the COVID-19-Associated Hospitalization Surveillance Network (COVID-NET) were analyzed with vaccination coverage data from state immunization information systems (IISs) for the COVID-NET catchment area (approximately 4.8 million persons). Among adults aged 65-74 years, effectiveness of full vaccination in preventing COVID-19-associated hospitalization was 96% (95% confidence interval [CI] = 94%-98%) for Pfizer-BioNTech, 96% (95% CI = 95%-98%) for Moderna, and 84% (95% CI = 64%-93%) for Janssen vaccine products. Effectiveness of full vaccination in preventing COVID-19-associated hospitalization among adults aged ≥75 years was 91% (95% CI = 87%-94%) for Pfizer-BioNTech, 96% (95% CI = 93%-98%) for Moderna, and 85% (95% CI = 72%-92%) for Janssen vaccine products. COVID-19 vaccines currently authorized in the United States are highly effective in preventing COVID-19-associated hospitalizations in older adults. In light of real-world data demonstrating high effectiveness of COVID-19 vaccines among older adults, efforts to increase vaccination coverage in this age group are critical to reducing the risk for COVID-19-related hospitalization.

来源:MMWR Morb Mortal Wkly Rep,查看原文。版权归原作者所有。

引用

  1. Moline HL, Whitaker M, Deng L, et al. Effectiveness of COVID-19 Vaccines in Preventing Hospitalization Among Adults Aged ≥65 Years - COVID-NET, 13 States, February-April 2021. MMWR Morb Mortal Wkly Rep. 2021. PMID: 34383730. doi:10.15585/mmwr.mm7032e3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。